JUPITER, Fla., April 24, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced today that it has launched Fibrezyme® G4, a high performance cellulase enzyme product designed to enhance paper and textile quality, while improving the economics of our customers' manufacturing processes.
(Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )
Fibrezyme® G4 has shown to reduce energy requirements and increase production rates for pulp and paper manufacturers. In addition, Fibrezyme® G4 enhances and restores fiber strength and increases inter-fiber bonding in paper-making applications. In the textile industry, Fibrezyme® G4 will be used to soften denim and create a stonewashed look for blue jeans. Fibrezyme® G4 operates under wide pH and temperature ranges allowing for improved integration into a variety of pulp and paper and textile manufacturing processes.
Danai Brooks, Dyadic's Chief Operating Officer stated, "Fibrezyme® G4 is a new addition to our product portfolio and provides further evidence of the capabilities of Dyadic's C1 platform technology. We expect two key markets to be China and South Asia, which are growing and open to new entrants like Dyadic. Interest in pulp and paper enzymes in South Asia continues to grow in both commercial applications and innovation. South Asia is also one of the world's largest textile enzyme markets. Over the past year, China has become an important part of our pulp and paper strategy as we continue to strengthen our commercial relationships in that country. In addition, government policy is increasingly focused on the environmental impact of mills, which is expected to drive up demand for enzymes like Fibrezyme® G4."
Dyadic's Vice President of Operations, Rich Jundzil, added "Fibrezyme® G4 represents the next generation of C1-based products produced using the White Strain, the latest addition to Dyadic's patented and proprietary C1 platform. In our manufacturing process, the White Strain produces purer proteins, which allows us to make more of the protein of interest with a reduction in unwanted side activities. This technology allows for more efficient industrial scale production of highly targeted enzymes that are specifically designed to meet the needs of our customers. The White Strain continues to broaden the reach of the C1 platform into new applications for the pharmaceutical, food, animal feed, brewing, baking, and other industrial markets." Fibrezyme® G4 became available to customers beginning in March of 2014. Please direct inquiries to [email protected].
About Dyadic
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at (www.otcmarkets.com/stock/DYAI/quote).
Cautionary Note Regarding Forward-Looking Statements
Certain statements contained in this press release are "forward-looking statements" within the meaning of the federal securities laws. Statements about our beliefs and expectations regarding our technology platform and product portfolio, our ability to efficiently develop new products and new applications for our products and our ability to expand into new markets, may constitute forward-looking statements. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. If Dyadic does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements. Factors that could cause results to differ materially include, but are not limited to: (1) whether our new and existing products will achieve commercial success; (2) whether our new products will result in any new customers, partners, collaborations or licensing agreements; (3) Dyadic's research and development efforts and (4) other factors discussed in Dyadic's publicly available filings, including the risk factors included in Dyadic's Initial Information and Disclosure Statement filed with the OTC Markets Group on March 11, 2014.
SOURCE Dyadic International, Inc.
Share this article